Keymed Biosciences (HKG:2162) said Friday that Kangyueda sales more than tripled to roughly 600 million yuan for the first three quarters this year, driven by strong demand and broader hospital access to the treatment, according to a same-day bourse filing.
Additionally, the biotechnology company said Chinese health regulators have approved Kangyueda's marketing application for a fourth indication, including both vials and pre-filled auto-injector pens of the treatment, to now treat moderate-to-severe atopic dermatitis in adolescents.
Shares were last up 8.2% in afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments